Martin Suda Resolution-based methods for linear temporal reasoning

M. Suda

Abstract:

What problem does this paper attempt to address?

Genetic control of thymus-derived cell function. V. Mitrogen-stimulated deoxyribonucleic acid synthesis by thymus, spleen, and lymph node cells from the Biozzi high and low antibody-producing lines of mice.

R. M. Williams,B. Benacerraf

1975-04-01

Transplantation

Abstract:
Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The "THESIS"* collaboration (* T reatment of H ypothyroidism in Europe by S pecialists, an I nternational S urvey)

Roberto Attanasio,Miloš Žarković,Enrico Papini,Endre V. Nagy,Roberto Negro,Petros Perros,Ersin Akarsu,Maria Alevizaki,Göksun Ayvaz,Tomasz Bednarczuk,Biljana Beleslin,Eszter Berta,Miklos Bodor,Anna Maria Borissova,Mihail Boyanov,Camille Buffet,Maria-Cristina Burlacu,Jasmina Ciric,Juan J Díez,Harald Dobnig,Valentin V Fadeyev,Benjamin CT Field,Eric Fliers,Dagmar Führer,Juan Carlos Galofré,Tommi Hakala,Jan Jiskra,Peter A. Kopp,Michael Krebs,Michal Kršek,Martin Kuzma,Mikael Lantz,Ivica Lazúrová,Laurence Leenhardt,Vitaliy Luchytskiy,Francisca Marques Puga,Anne McGowan,Saara Metso,Carla Moran,Tatyana Morgunova,Dan Alexandru Niculescu,Božidar Perić,Tereza Planck,Catalina Poiana,Eyal Robenshtok,Patrick Olivier Rosselet,Marek Ruchala,Kamilla Ryom Riis,Alla Shepelkevich,Mykola D. Tronko,David Unuane,Irfan Vardarli,W. Edward Visser,Andromachi Vryonidou,Younes Ramazan Younes,Laszlo Hegedus

DOI: https://doi.org/10.1089/thy.2023.0580

IF: 6.506

2024-02-19

Thyroid

Abstract:Background. Hypothyroidism is common, however, aspects of its treatment remain controversial. Our survey aimed at documenting treatment choices of European thyroid specialists and exploring how patients' persistent symptoms, clinician demographics, and geo-economic factors relate to treatment choices. Methods. 17,247 thyroid specialists from 28 countries were invited to participate in an online questionnaire survey. The survey included respondent demographic data and treatment choices for hypothyroid patients with persistent symptoms. Geo-economic data for each country were included in the analyses. Results. The response rate was 32.9% (6,058 respondents out of 17,247 invitees). Levothyroxine (LT4) was the initial treatment preferred by the majority (98.3%). Persistent symptoms despite normal serum thyrotropin (TSH) while receiving LT4 treatment were reported to affect up to 10.0% of patients by 75.4% of respondents, while 28.4% reported an increasing such trend in the past five years. The principal explanations offered for patients' persistent symptoms were psychosocial factors (77.1%), comorbidities (69.2%), and unrealistic patient expectations (61.0%). Combination treatment with LT4 + liothyronine (LT3) was chosen by 40.0% of respondents for patients who complained of persistent symptoms despite a normal TSH. This option was selected more frequently by female thyroid specialists, with high-volume practice, working in countries with high gross national income per capita. Conclusions. The perception of patients' dissatisfaction reported by physicians seems lower than that described by hypothyroid patients in previous surveys. LT4+LT3 treatment is used frequently by thyroid specialists in Europe for persistent hypothyroid-like symptoms even if they generally attribute such symptoms to non-endocrine causes and despite the evidence of non-superiority of the combined over the LT4 therapy. Pressure by dissatisfied patients on their physicians for LT3-containing treatments is a likely explanation. The association of the therapeutic choices with the clinician demographic characteristics and geo-economic factors in Europe is a novel information and requires further investigation.

endocrinology & metabolism
The pharmacokinetics of diethanolamine in Sprague-Dawley rats following intravenous administration.

A. L. Mendrala,J. Waechter,G. A. Bormett,M. Bartels,W. Stott

DOI: https://doi.org/10.1016/S0278-6915(01)00036-9

IF: 4.3

2001-09-01

Food and Chemical Toxicology

Abstract:
Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

Nicole Lafontaine,Suzanne J. Brown,Petros Perros,Enrico Papini,Endre V. Nagy,Roberto Attanasio,Laszlo Hegedüs,John P. Walsh

DOI: https://doi.org/10.1111/cen.15049

2024-03-12

Clinical Endocrinology

Abstract:Objective Hypothyroidism is a common endocrine condition usually managed with levothyroxine (LT4). However, controversy remains around the use of liothyronine (LT3). We aimed to investigate the practices of Australian endocrinologists when managing patients with hypothyroidism, their use of LT3 + LT4 combination therapy and use of thyroid hormones in euthyroid patients. Design and Participants Members of the Endocrine Society of Australia (ESA) were invited to participate in an online questionnaire. Measurements We analysed questionnaires that had complete demographic data. Results Eighty‐seven questionnaires fulfilled the criteria. LT4 was used as first line treatment for hypothyroidism by all respondents. Only 45% reported that their patients were dispensed the brand of LT4 that they recommend. LT3 (alone or in combination) was prescribed by 44% in their clinical practice. Although 49% of respondents would consider LT3 + LT4 in patients with normal TSH who had ongoing symptoms of hypothyroidism, the inability of LT4 to restore normal physiology was ranked the least likely explanation for persistent symptoms and only 32% would consider it for themselves if they were diagnosed with hypothyroidism. The majority (55%), in accordance with evidence, would not prescribe thyroid hormone to euthyroid individuals but 39% would consider use in euthyroid female infertility with high levels of thyroid antibodies and 11% in euthyroid patients with a simple goitre growing over time. LT4 use in pregnancy was variable among members. Conclusions Australian endocrinologists mostly follow international guidelines when prescribing thyroid hormone therapy and many prescribe combination LT3 and LT4 therapy, particularly for patients who remain symptomatic on LT4 monotherapy. Prescribing practices are largely similar to other countries who have completed similar questionnaires.

endocrinology & metabolism
Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey

Juan C Galofré,Roberto Attanasio,Laszlo Hegedüs,Endre Nagy,Roberto Negro,Enrico Papini,Petros Perros,Juan J Díez

DOI: https://doi.org/10.1016/j.endien.2022.07.001

Abstract:Background: Hypothyroidism is one of the leading conditions in endocrinology. Despite that fact, clinical indications for treatment still vary among Spanish specialists. Aims: To identify attitudes of Spanish specialists relating to the use of levothyroxine (LT4) and the management of hypothyroidism. Methods: The members of the Sociedad Española de Endocrinología y Nutrición (Spanish Society of Endocrinology and Nutrition) were invited to participate in a web-based survey. The survey, initially in English, was modified to reflect in accordance with the availability of thyroid hormone formulations in Spain. Results: A total of 505 of 1956 (25.8%) members (66% female) completed the survey; 97.4% declared that LT4 is the first-line therapy for hypothyroidism. The indications for LT4 therapy in euthyroidism were infertility in thyroid antibody-positive women (48.5%) and simple goitre (21.2%). However, 44.2% of specialists reported that there was no indication for LT4 therapy in such patients. Only a minority of respondents (2.6%) considered combining LT4 with liothyronine as the treatment of choice from inception, whereas 49% stated that it should never be used. Conclusions: The standard of treatment of hypothyroidism in Spain is almost exclusively with LT4 tablets. Availability of other formulations of LT4 or combination therapy for hypothyroidism management remains to be explored, especially in patients with persistent symptoms. Notably, non-evidence-based use of LT4 is widely practiced in Spain for euthyroid women with autoimmune thyroiditis and fertility issues.
Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France

Camille Buffet,Lisa Belin,Roberto Attanasio,Roberto Negro,Lazlo Hegedüs,Endre V Nagy,Enrico Papini,Petros Perros,Laurence Leenhardt

DOI: https://doi.org/10.1016/j.ando.2021.11.002

Abstract:Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.
Comment on Ran et al.: floating knee: a modified Fraser's classification and the results in a series of 28 cases.

Siddhartha Sharma,Vishal Kumar,Mandeep Singh Dhillon

DOI: https://doi.org/10.1016/j.injury.2013.04.032

IF: 2.687

2013-11-01

Injury

Abstract:
The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

Bernadette Biondi,Luigi Bartalena,David S. Cooper,Laszlo Hegedüs,Peter Laurberg,George J. Kahaly

DOI: https://doi.org/10.1159/000438750

2015-01-01

European Thyroid Journal

Abstract:Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.

endocrinology & metabolism
Genetic analysis carried out on blood-spots of phenylalanine hydroxylase-deficient newborns detected by northeastern Italian neonatal screening.

M. Zaffanello,G. Zamboni,M. Maselli,A. Gandini,M. Camilot,C. Maffeis,A. Burlina,L. Tató

DOI: https://doi.org/10.1089/GTE.2005.9.133

2005-06-08

Genetic Testing

Abstract:The aim of this work was to perform genetic analysis on 18 different blood-spot samples collected from neonates detected as hyperphenylalaninemic by Northeastern Italian screening program. DNA was extracted from blood-spots. Exons/introns of PAH gene were amplified by polymerase chain reaction (PCR), and PCR products were purified and sequenced with both forward and reverse primers. The most frequent mutations were IVS12nt1g>a (16.7%) and R408W, P281L and L48S (all together 11.1%). As expected, compound heterozygosity was the usual finding; homozygosity was found only in two patients with R158Q and IVS2nt5g>c mutations. The V230I mutation was reported for the first time in Italy. We found six previously described polymorphisms (V245V, IVS4nt47c>t, IVS2nt19t>c, IVS3nt-22c>t, IVS5nt-54a>g, and E280>Q280). To our knowledge, four genotypes were not previously described: R158Q/V230I present in one patient with classical PKU; and L48S/R408Q, A403V/IVS2nt-13t>g, and G272X/V230I present in patients showing HPA phenotype. Most of the mutations were located in the exons 12 and 7 and in exon/intron 2 (83.3% detection of total mutations in PKU or HPA patients of Northeastern Italy). From a practical viewpoint, the genetic analysis of blood-spots collected on Guthrie cards for neonatal screening for PKU could be a simple method to establish the genotype of neonates. Consequently, the genotype/phenotype correlation could lead to a more accurate diagnosis and prognosis for families.
Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation

Anna L. Mitchell,Laszlo Hegedüs,Miloš Žarković,Janis L. Hickey,Petros Perros

DOI: https://doi.org/10.1111/cen.14340

2020-12-17

Clinical Endocrinology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Dissatisfaction with treatment and impaired quality of life (QOL) are reported amongst people with treated hypothyroidism. We aimed to gain insight into this.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Design and patients</h3><p>We conducted an online survey of individuals with self‐reported hypothyroidism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>969 responses were analysed. Dissatisfaction with treatment was common (77.6%) and overall QOL scores were low. Patient satisfaction did not correlate with type of thyroid hormone treatment, but treatment with combination levothyroxine (L‐T4) and liothyronine (L‐T3) or with desiccated thyroid extract (DTE) was associated with significantly better reported QOL than L‐T4 or L‐T3 monotherapies (p<0.001), however, multivariate analysis inclusive of other clinical parameters failed to confirm an association between type of thyroid hormone treatment and QOL or satisfaction. Multivariate analysis showed positive correlations between satisfaction and age (p=0.026), male gender (p=0.011), being under the care of a thyroid specialist (p<0.001), family doctor (GP) prescribing DTE or L‐T4+L‐T3 or L‐T3 (p<0.001), and being well informed about hypothyroidism (p<0.001); negative correlations were observed between satisfaction and negative experiences with L‐T4 (p<0.001) and expectations for more support from the GP (p<0.001), for L‐T4 to resolve all symptoms (p=0.004), and to be referred to a thyroid specialist (p<0.001). For QOL, positive correlations were with male gender (p=0.011) and duration of hypothyroidism (p=0.002); negative correlations were with age (p=0.027), visiting the GP more than 3 times before diagnosis (p<0.001), sourcing DTE or L‐T3 independently (p=0.014), negative experiences with L‐T4 (p=0.013), having expectations for L‐T4 to resolve all symptoms (p<0.001) and of more support from the GP (p=0.006).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Multiple parameters including prior healthcare experiences and expectations influence satisfaction with hypothyroidism treatment and QOL. Focusing on enhancing the patient experience and clarifying expectations at diagnosis may improve satisfaction and QOL.</p></section>

endocrinology & metabolism
Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

Roberto Negro,Miloš Žarković,Roberto Attanasio,Laszlo Hegedüs,Endre V. Nagy,Enrico Papini,Ersin Akarsu,Maria Alevizaki,Göksun Ayvaz,Tomasz Bednarczuk,Biljana Nedeljković Beleslin,Eszter Berta,Miklos Bodor,Anna Maria Borissova,Mihail Boyanov,Camille Buffet,Maria‐Cristina Burlacu,Jamina Ćirić,Chagit Adler Cohen,Juan J. Díez,Harald Dobnig,Valentin Fadeyev,Benjamin C. T. Field,Eric Fliers,Dagmar Führer,Juan C. Galofré,Tommi Hakala,Jiskra Jan,Peter Kopp,Michael Krebs,Michal Kršek,Martin Kužma,Laurence Leenhardt,Vitaliy Luchytskiy,Francisca Marques Puga,Anne McGowan,Miguel Melo,Saara Metso,Carla Moran,Tatyana Morgunova,Dan Alexandru Niculescu,Božidar Perić,Tereza Planck,Catalina Poiana,Eyal Robenshtok,Patrick Olivier Rosselet,Marek Ruchala,Kamilla Ryom Riis,Alla Shepelkevich,Mykola Tronko,David Unuane,Irfan Vardarli,Edward Visser,Andromachi Vryonidou,Younes R. Younes,Petros Perros

DOI: https://doi.org/10.1111/cen.15099

2024-06-12

Clinical Endocrinology

Abstract:Objectives The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of the study was to document the use of LT4 by European thyroid specialists in such patients. Design The data presented derive from Treatment of Hypothyroidism in Europe by Specialists, an International Survey (THESIS), a questionnaire conducted between 2019 and 2021 to document the management of hypothyroidism by European thyroid specialists. Here, we report the aggregate results on the use of LT4 in infertile, euthyroid women with positive TPOAb. Results A total of 2316/5406 (42.8%) respondents stated that LT4 may be indicated in TPOAb positive euthyroid women with infertility. The proportion of those replying positively to this question varied widely across different countries (median 39.4, range 22.9%–83.7%). In multivariate analyses males (OR: 0.8; CI: 0.7–0.9) and respondents >60 years (OR: 0.7; 0.6–0.8) were the least inclined to consider LT4 for this indication. Conversely, respondents managing many thyroid patients ("weekly" [OR: 1.4; CI: 1.0–1.9], "daily" [OR: 1.8; CI: 1.3–2.4]) and practicing in Eastern Europe (OR: 1.5; CI: 1.3–1.9) were most likely to consider LT4. Conclusions A remarkably high number of respondents surveyed between 2019 and 2021, would consider LT4 treatment in TPOAb positive euthyroid women with infertility. This view varied widely across countries and correlated with sex, age and workload, potentially influencing patient management. These results raise concerns about potential risks of overtreatment.

endocrinology & metabolism
Rapid alterations of serum fatty acids with the intravenous administration of an arachidonate solution.

S. Hatziantoniou,E. Giamarellos‐Bourboulis,S. Skiathitis,C. Demetzos,I. Donta,G. Papaioannou,A. Dionyssiou-Asteriou,P. Karayannacos,H. Giamarellou

DOI: https://doi.org/10.1016/J.PLEFA.2003.09.002

2004-05-01

Abstract:
Thyroid nodules: a review of current guidelines, practices, and prospects

H Gharib,E Papini,R Paschke

DOI: https://doi.org/10.1530/eje-08-0135

2008-11-01

European Journal of Endocrinology

Abstract:In 2006, two major society-sponsored guidelines and one major consensus statement for thyroid diagnosis and management were published by: the American Association of Clinical Endocrinologists/Associazione Medici Endocrinologi (AACE/AME); the American Thyroid Association (ATA); and the European Thyroid Association (ETA). A careful review of these guidelines reveals that despite many similarities, significant differences are also present, likely reflecting differences in practice patterns, interpretation of existing data, and availability of resources in different regions. The methodology of the guidelines is similar, but a few differences in the rating scale make a rapid comparison of the strength of both evidence and recommendations difficult for the use in current clinical practice. Some recommendations are based mostly on experts' opinion. Thus, a same recommendation may be based on a different evidence; on the other hand, sometimes the same evidence may induce a different recommendation. Therefore, efforts are needed to produce a few high-quality clinical studies to close the evidence gaps in the still controversial fields of thyroid disease and to create a joint task force of the most authoritative societies in the field of thyroid disease in order to reach a common document for clinical practice recommendations.

endocrinology & metabolism
How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey

Neil Lawrence,Tim Cheetham,Charlotte Elder

DOI: https://doi.org/10.1111/cen.14046

Abstract:Objective: We aimed to document current practice in the medical management of paediatric hyperthyroidism in the UK and compare to international recommendations. Design: A 27-question online survey distributed via an electronic newsletter in August 2018. Participants: Responses from 48 members (11%) of the British Society for Paediatric Endocrinology and Diabetes. Measurements: Information about antithyroid drug (ATD) preference, treatment duration, monitoring of full blood count (FBC), management of neutropaenia, agranulocytosis screening and patient education. Results: Carbimazole is favoured by 98% of respondents and a "dose titration" regimen preferred over "block and replace" (65% vs 29%). TRAbs (thyroid-stimulating hormone receptor antibodies) are used for diagnostic purposes by 85% and by 33% to look for evidence of disease remission. The majority (81%) treat for a minimum of 2 years before considering a trial off ATD. All respondents reported that they "always/usually" warn their patients about the risk of agranulocytosis before starting ATD, but written information is "rarely/never" provided by 63%. Sore throat (98%) and fever (92%) are the most commonly cited symptoms used to alert a patient to possible agranulocytosis. FBC is measured prior to treatment by 65% and measured periodically during treatment by 70%. Conclusions: The management of paediatric hyperthyroidism with ATDs in the UK is not consistent with all international recommendations because a block and replace ATD regimen remains widely used. TRAbs are utilized at presentation, but underused for detecting disease remission. National consensus guidelines and written patient information may refine the management of paediatric patients on ATDs.
Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment

M Žarković,W Wiersinga,P Perros,L Bartalena,S Donati,O Okosieme,D Morris,N Fichter,J Lareida,C Daumerie,M-C Burlacu,G J Kahaly,S Pitz,B Beleslin,J Ćirić,G Ayvaz,O Konuk,F B Törüner,M Salvi,D Covelli,N Curro,L Hegedüs,T Brix,EUGOGO (European Group on Graves’ Orbitopathy)

DOI: https://doi.org/10.1007/s40618-020-01320-7

Abstract:Purpose: Whereas antithyroid drugs (ATD) are the preferred treatment modality for Graves' hyperthyroidism (GH), there is still controversy about the optimal regimen for delivering ATD. To evaluate whether 'Block and Replace' (B + R) and 'Titration' (T) regimes are equivalent in terms of frequency of euthyroidism and Graves' Orbitopathy (GO) during ATD therapy. Methods: A prospective multicentre observational cohort study of 344 patients with GH but no GO at baseline. Patients were treated with ATD for 18 months according to B + R or T regimen in line with their institution's policy. Results: Baseline characteristics were similar in both groups. In the treatment period between 6 and 18 months thyrotropin (TSH) slightly increased in both groups, but TSH was on average 0.59 mU/L (95% CI 0.27-0.85) lower in the B + R group at all time points (p = 0.026). Serum free thyroxine (FT4) remained stable during the same interval, with a tendency to higher values in the B + R group. The point-prevalence of euthyroidism (TSH and FT4 within their reference ranges) increased with longer duration of ATD in both groups; it was always higher in the T group than in the B + R group: 48 and 24%, respectively, at 6 months, 81 and 58% at 12 months, and 87 and 63% at 18 months (p < 0.002). There were no significant differences between the B + R and T regimens with respect to the fall in thyrotropin binding inhibiting immunoglobulins (TBII) or thyroid peroxidase antibodies (TPO-Ab). GO developed in 15.9% of all patients: 9.1 and 17.8% in B + R group and T group, respectively, (p = 0.096). GO was mild in 13% and moderate-to-severe in 2%. Conclusion: The prevalence of biochemical euthyroidism during treatment with antithyroid drugs is higher during T compared to B + R regimen. De novo development of GO did not differ significantly between the two regimens, although it tended to be higher in the T group. Whether one regimen is clinically more advantageous than the other remains unclear.
Treating subclinical hypothyroidism in individuals with or without mental health problems -A Delphi based expert consensus study in two countries

Ingrid Lieber,Christina Maria Van Der Feltz-Cornelis,Salman Razvi,Andrew S Moriarty,Scott Wilkes,Michael Ott,Julie Mannchen,Mats Eliasson,Ursula Werneke

DOI: https://doi.org/10.3389/fendo.2023.1204842

2023-07-12

Abstract:Background: Subclinical hypothyroidism (SCH) is a common endocrine problem with prevalence estimates between 4% and 20%. Symptoms are often non-specific but can substantially affect well-being leading to repeated medical consultations. The effect of thyroid hormone replacement therapy (THRT) in patients with SCH remains uncertain. Current guidelines, limited by the lack of high-quality evidence, have been controversial with limited adherence in clinical practice. Methods: Three-round modified Delphi method to establish consensus regarding diagnosis and treatment of individuals with SCH with and without affective disorder or anxiety, conducted with clinicians from three specialties, general practice, endocrinology and psychiatry, and two countries, Sweden and the United Kingdom. Results: Sixty clinicians, 20 per specialty, were recruited. Fifty-three (88%) participants completed all three rounds. The participants reached consensus on five of the 26 practice statements that (a) repeated testing was required for the diagnosis of subclinical hypothyroidism, (b) antibody screening should usually occur, and (c and d) antibody screening would strengthen the indication for thyroid hormone replacement therapy in both individuals with or without affective disorder or anxiety. The participants disagreed with (e) a requirement of a TSH threshold ≥ 20 mIU/L for thyroid hormone replacement therapy start. Psychiatrists and GPs but not endocrinologists, agreed that there was a frequent discrepancy between laboratory results and clinical symptoms, and disagreed that testing for thyroid dysfunction was overused in patients presenting with depression or anxiety, or fatigue. Conclusions: In many aspects, attitudes toward diagnosing and treating SCH remain diverse. The inability of our Delphi panel to achieve consensus on most items and the disagreement with a TSH ≥ 20 mIU/L threshold for treatment suggest that the concept of SCH may need rethinking with a better understanding of the hypothalamic-pituitary-thyroid physiology. Given that the scientific evidence is currently not conclusive, guidelines in this area should not be taken as definitive.
2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action

Luca Persani,Patrice Rodien,Carla Moran,W Edward Visser,Stefan Groeneweg,Robin Peeters,Samuel Refetoff,Mark Gurnell,Paolo Beck-Peccoz,Krishna Chatterjee

DOI: https://doi.org/10.1530/ETJ-24-0125

2024-08-03

Abstract:Impaired sensitivity to thyroid hormones encompasses disorders with defective transport of hormones into cells, reduced hormone metabolism, and resistance to hormone action. Mediated by heritable single-gene defects, these rare conditions exhibit different patterns of discordant thyroid function associated with multisystem phenotypes. In this context, challenges include ruling out other causes of biochemical discordance, making a diagnosis using clinical features together with the identification of pathogenic variants in causal genes, and managing these rare disorders with a limited evidence base. For each condition, the present guidelines aim to inform clinical practice by summarizing key clinical features and useful investigations, criteria for molecular genetic diagnosis, and pathways for management and therapy. Specific, key recommendations were developed by combining the best research evidence available with the knowledge and clinical experience of panel members, to achieve a consensus.
Temporal trends in the clinical presentation of Graves’ orbitopathy: a single–center retrospective study

R. Le Moli,A. Naselli,F. Lo Giudice,G. Costanzo,F. Frasca,A. Belfiore

DOI: https://doi.org/10.1007/s40618-024-02332-3

2024-03-15

Journal of Endocrinological Investigation

Abstract:Abstract Purpose Graves’ ophthalmopathy (GO) is an autoimmune disease that affects orbital soft tissues and represents the most common extrathyroidal manifestation of Graves’ disease (GD). The European Group of Graves’ Ophthalmopathy (EUGOGO) has attempted to shed light on the European epidemiological picture of GO, suggesting that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation. There are no studies that focus this issue on the population of our area; we aimed to evaluate the trend of GO clinical presentation in our outpatient clinic through an observation period of 10 years. Methods We compared 55 consecutive patients, 11 males (F) and 44 females (M), who came to our observation from January 2005 to December 2006 [Group 1 (G1)], with 56 patients, 15 males, and 41 females, who were referred to us from 2015 to 2016 [Group 2 (G2)]. We studied the following putative predictors of GO presentation and severity: thyroid function, smoking, diabetes, hypercholesterolemia, time from GO diagnosis to referral to our thyroid centre (TGOD), sex and age. Results GO severity was significantly reduced in G2 vs. G1 ( p = 0.04). TGOD ≥ 3 months was related to clinical characteristics of GO (severity and Clinical Activity Score ≥ 4) and was an independent predictor of GO severity ( p = 0.01). The other variables evaluated had no independent effects. Conclusions We found that GO severity at presentation was significantly reduced over a ten-year observation period (2005–2006 vs. 2015–2016) in GO patients referred to our tertiary thyroid centre. TGOD ≥ 3 months was an independent predictor of GO severity.

endocrinology & metabolism
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

J. Jonklaas,K. Burman,Brian W Kim,A. Cappola,D. Cooper,A. Bianco,Anna M. Sawka,Francesco S Celi,M. Rosenthal,A. Bauer,R. Peeters

DOI: https://doi.org/10.1089/thy.2014.0028

IF: 6.506

2014-12-01

Thyroid

Abstract:BACKGROUND A number of recent advances in our understanding of thyroid physiology may shed light on why some patients feel unwell while taking levothyroxine monotherapy. The purpose of this task force was to review the goals of levothyroxine therapy, the optimal prescription of conventional levothyroxine therapy, the sources of dissatisfaction with levothyroxine therapy, the evidence on treatment alternatives, and the relevant knowledge gaps. We wished to determine whether there are sufficient new data generated by well-designed studies to provide reason to pursue such therapies and change the current standard of care. This document is intended to inform clinical decision-making on thyroid hormone replacement therapy; it is not a replacement for individualized clinical judgment. METHODS Task force members identified 24 questions relevant to the treatment of hypothyroidism. The clinical literature relating to each question was then reviewed. Clinical reviews were supplemented, when relevant, with related mechanistic and bench research literature reviews, performed by our team of translational scientists. Ethics reviews were provided, when relevant, by a bioethicist. The responses to questions were formatted, when possible, in the form of a formal clinical recommendation statement. When responses were not suitable for a formal clinical recommendation, a summary response statement without a formal clinical recommendation was developed. For clinical recommendations, the supporting evidence was appraised, and the strength of each clinical recommendation was assessed, using the American College of Physicians system. The final document was organized so that each topic is introduced with a question, followed by a formal clinical recommendation. Stakeholder input was received at a national meeting, with some subsequent refinement of the clinical questions addressed in the document. Consensus was achieved for all recommendations by the task force. RESULTS We reviewed the following therapeutic categories: (i) levothyroxine therapy, (ii) non-levothyroxine-based thyroid hormone therapies, and (iii) use of thyroid hormone analogs. The second category included thyroid extracts, synthetic combination therapy, triiodothyronine therapy, and compounded thyroid hormones. CONCLUSIONS We concluded that levothyroxine should remain the standard of care for treating hypothyroidism. We found no consistently strong evidence for the superiority of alternative preparations (e.g., levothyroxine-liothyronine combination therapy, or thyroid extract therapy, or others) over monotherapy with levothyroxine, in improving health outcomes. Some examples of future research needs include the development of superior biomarkers of euthyroidism to supplement thyrotropin measurements, mechanistic research on serum triiodothyronine levels (including effects of age and disease status, relationship with tissue concentrations, as well as potential therapeutic targeting), and long-term outcome clinical trials testing combination therapy or thyroid extracts (including subgroup effects). Additional research is also needed to develop thyroid hormone analogs with a favorable benefit to risk profile.

Medicine
Italian Guidelines For The Management Of Non-Functioning Benign And Locally Symptomatic Thyroid Nodules

Roberto Attanasio,Enrico Papini,Anna Crescenzi,Annamaria D'Amore,Maurilio Deandrea,Anna De Benedictis,Andrea Frasoldati,Roberto Garberoglio,Rinaldo Guglielmi,Celestino Pio Lombardi,Giovanni Mauri,Rosa Elisa Miceli,Soraya Puglisi,Teresa Rago,Domenico Salvatore,Vincenzo Triggiani,Dominique Van Doorne,Zuzana Mitrova,Rosella Saulle,Simona Vecchi,Michele Basile,Alessandro Scoppola,Agostino Paoletta,Agnese Persichetti,Irene Samperi,Renato Cozzi,Franco Grimaldi,Marco Boniardi,Angelo Camaioni,Rossella Elisei,Edoardo Guastamacchia,Giulio Nati,Tommaso Novo,Massimo Salvatori,Stefano Spiezia,Gianfranco Vallone,Michele Zini

DOI: https://doi.org/10.2174/1871530323666230201104112

2023-02-18

Endocrine, Metabolic and Immune Disorders - Drug Targets

Abstract:Aim: This guideline (GL) is aimed at providing a reference for the management of non-functioning, benign thyroid nodules causing local symptoms in adults outside of pregnancy. Methods: This GL has been developed following the methods described in the Manual of the National Guideline System. For each question, the panel appointed by Associazione Medici Endocrinology (AME) identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as "critical" and "important" were considered in the systematic review of evidence and only those classified as "critical" were considered in the formulation of recommendations. Results: The present GL contains recommendations about the respective roles of surgery and minimally invasive treatments for the management of benign symptomatic thyroid nodules. We suggest hemithyroidectomy plus isthmectomy as the first-choice surgical treatment, provided that clinically significant disease is not present in the contralateral thyroid lobe. Total thyroidectomy should be considered for patients with clinically significant disease in the contralateral thyroid lobe. We suggest considering thermo-ablation as an alternative option to surgery for patients with a symptomatic, solid, benign, single, or dominant thyroid nodule. These recommendations apply to outpatients, either in primary care or when referred to specialists. Conclusion: The present GL is directed to endocrinologists, surgeons, and interventional radiologists working in hospitals, in territorial services, or private practice, general practitioners, and patients. The available data suggest that the implementation of this GL recommendations will result in the progressive reduction of surgical procedures for benign thyroid nodular disease, with a decreased number of admissions to surgical departments for non-malignant conditions and more rapid access to patients with thyroid cancer. Importantly, a reduction of indirect costs due to long-term replacement therapy and the management of surgical complications may also be speculated.

pharmacology & pharmacy,immunology,endocrinology & metabolism

Martin Suda Resolution-based methods for linear temporal reasoning

Genetic control of thymus-derived cell function. V. Mitrogen-stimulated deoxyribonucleic acid synthesis by thymus, spleen, and lymph node cells from the Biozzi high and low antibody-producing lines of mice.

Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The "THESIS"* collaboration (* T reatment of H ypothyroidism in Europe by S pecialists, an I nternational S urvey)

The pharmacokinetics of diethanolamine in Sprague-Dawley rats following intravenous administration.

Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey

Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France

Comment on Ran et al.: floating knee: a modified Fraser's classification and the results in a series of 28 cases.

The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

Genetic analysis carried out on blood-spots of phenylalanine hydroxylase-deficient newborns detected by northeastern Italian neonatal screening.

Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation

Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

Rapid alterations of serum fatty acids with the intravenous administration of an arachidonate solution.

Thyroid nodules: a review of current guidelines, practices, and prospects

How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey

Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment

Treating subclinical hypothyroidism in individuals with or without mental health problems -A Delphi based expert consensus study in two countries

2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action

Temporal trends in the clinical presentation of Graves’ orbitopathy: a single–center retrospective study

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Italian Guidelines For The Management Of Non-Functioning Benign And Locally Symptomatic Thyroid Nodules